These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29687559)

  • 1. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
    Hegen H; Bsteh G; Berger T
    Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
    Mayssam EN; Eid C; Khoury SJ; Hannoun S
    Mult Scler Relat Disord; 2020 May; 40():101935. PubMed ID: 31951861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
    Tsantes E; Curti E; Collura F; Bazzurri V; Fiore A; Granella F
    J Neurol Sci; 2020 Jul; 414():116827. PubMed ID: 32289575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
    Newsome SD; Binns C; Kaunzner UW; Morgan S; Halper J
    Neurol Ther; 2023 Dec; 12(6):1909-1935. PubMed ID: 37819598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NEDA treatment target? No evident disease activity as an actionable outcome in practice.
    Parks NE; Flanagan EP; Lucchinetti CF; Wingerchuk DM
    J Neurol Sci; 2017 Dec; 383():31-34. PubMed ID: 29246616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
    Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
    Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
    Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence of disease activity in multiple sclerosis patients.
    Matta AP; Nascimento OJ; Ferreira AC; Magalhães TN; Benevides TP; Kirmse A; Dib JG; Cal H; Orsini M; Araujo LM
    Expert Rev Neurother; 2016 Nov; 16(11):1279-1284. PubMed ID: 27352830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
    Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
    Coyle PK; Reder AT; Freedman MS; Fang J; Dangond F
    J Neurol Sci; 2017 Aug; 379():151-156. PubMed ID: 28716230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
    Damasceno A; Damasceno BP; Cendes F
    Mult Scler; 2016 Jan; 22(1):64-72. PubMed ID: 26432855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
    Guevara C; Garrido C; Martinez M; Farias GA; Orellana P; Soruco W; Alarcón P; Diaz V; Silva C; Kempton MJ; Barker G; de Grazia J
    Front Neurol; 2019; 10():788. PubMed ID: 31396148
    [No Abstract]   [Full Text] [Related]  

  • 19. "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Giovannoni G; Tomic D; Bright JR; Havrdová E
    Mult Scler; 2017 Aug; 23(9):1179-1187. PubMed ID: 28381105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Sormani MP; Muraro PA; Saccardi R; Mancardi G
    Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.